The Myriad case – September 2012

In its decision of 16 August 2012, in the Myriad case, (, the Court of Appeals for the Federal Circuit United States concluded that the compositions of man-made materials, including isolated DNA molecules, and screening methods that implement them are likely to be protected by a patent, if they satisfy the other criteria of patentability. In contrast, the Court upheld the decision of the District Court decision in the case v Mayo. Prometheus ( regarding the non patentability of diagnostic methods.

Comments are closed.